Summary: In a Phase II study, patients with advanced breast cancer resistant to antracyclines were treated with a combination of paclitaxel, ifosfamid and mitoxantron Paclitaxel was administered in the dose of 135 mg/m2 by 3-hour infusion. Altogether 65 cycles in 15 patients were administered, for an overall response rate of 46.6%. The most frequent toxicity was myelosupression. Non - hematological toxicities were never of clinical concern.
The combination is active in breast cancer patients resistant to antracyclines, and can be safely administered with standard premedication in an out-patient way.
The Combination Taxol+Ifosfamid+Mitoxantron in the Treatment of Advaced Breast Cancer
